The only issue with the vaccines currently in development is the low efficiency.
From seven clinical trials including 36,371 participants there was an estimated efficiency of 44%. If you take that figure and apply it to the rest of the population it leaves 56% of the population susceptible to dengue.
The fall back option of that 56% is hopefully going to be ISLA-101.
Here's an article on dengue vaccine efficiency where I got my figures from.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712597/
ISLAND PHARMACEUTICALS LIMITED ILA IPO Analysis, page-77
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
